Supplementary material Web view40.Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, Gobartt E, de...

Supplementary material

Table S1 Search Strategy for Humanistic Review Conducted for Embase® and

MEDLINE® Using Embase® Platform

No. Query

#1 'chronic obstructive lung disease'/syn OR 'chronic obstructive lung disease' OR 'chronic bronchitis'/syn OR 'chronic bronchitis' OR 'emphysema'/syn OR 'emphysema' OR (chronic* NEAR/3 bronchiti*):ab,ti OR (obstruct* NEAR/3 (pulmonary OR lung* OR airway* OR airflow* OR bronch* OR respirat*)):ab,ti

#2 moderat* OR sever* OR ‘serious’ OR ‘critical’ OR ‘end?stage’ OR ‘life?threatening’ OR ‘Moderate to severe’ OR stage?4 OR ‘moderate to very severe’ OR ‘gold b’ OR ‘gold d’ OR ‘gold-b’ OR ‘gold-d’ OR ‘gold stage b’ OR ‘gold stage d’ OR advance*

#3 #1 AND #2

#4 (utilit* NEAR/2 (measure* OR outcome* OR state* OR health OR score* OR weight* OR analysis)):ab,ti OR 'health utility index' OR 'hui' OR 'hrqol' OR 'hqol' OR 'quality of life'/exp OR 'quality of life' OR 'quality-of-life'/exp OR 'quality-of-life' OR qol OR utilit* NEXT/1 (score* OR value* OR evaluation*) OR health NEXT/2 utilit* OR ('health'/exp OR 'health' AND state NEXT/1 utilit*) OR hui OR (health NEXT/1 state* AND state* NEXT/1 preference*) OR 'quality adjusted life year'/exp OR 'quality adjusted life year' OR 'quality adjusted life' OR 'quality adjusted' NEXT/1 survival* OR qaly* OR qald* OR qale* OR qtime* OR 'disability adjusted life' OR daly* OR 'health survey'/exp OR 'health survey' OR hye* OR health*year*equivalent OR health NEAR/2 utility* OR 'wellbeing'/exp OR 'wellbeing' OR quality NEAR/2 well*being OR qwb OR willingness NEAR/2 pay OR standard NEAR/2 gamble OR disutili* OR time NEAR/2 trade*off OR tto OR 'discrete choice' NEXT/1 experiment* OR 'short form 36'/exp OR 'short form 36' OR 'sf36' OR 'sf-36' OR 'sf 36' OR 'short form 12'/exp OR 'short form 12' OR 'sf12' OR 'sf-12' OR 'sf 12' OR 'short form 6' OR 'sf6' OR 'sf-6' OR 'sf 6' OR 'euroqol' OR euro*qol OR 'eq5d' OR 'eq-5d' OR 'eq 5d' OR rosser OR (visual NEXT/1 analog* AND analog* NEXT/1 scale*) OR 'st george?s respiratory questionnaire' OR 'sgrq':ab,ti OR 'treatment satisfaction questionnaire for medication' OR 'tsqm':ab,ti OR ((treat* OR medi*) NEAR/3 satisfact*):ab,ti OR 'patient reported outcome*' OR 'tdi':ab,ti OR 'mrc':ab,ti OR 'medical research council dyspnoea scale':ab,ti OR 'emsci':ab,ti OR 'cat':ab,ti OR 'copd assessment test':ab,ti OR 'ccq':ab,ti OR 'clinical copd questionnaire':ab,ti OR 'chronic respiratory disease questionnaire':ab,ti OR 'crq':ab,ti

#5 #3 AND #4

#6 #5 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/lim OR [review]/lim)

#7 #5 NOT #6

#8 #7 AND [animals]/lim

#9 #7 NOT #8

#10 #9 AND ([embryo]/lim OR [fetus]/lim OR [newborn]/lim OR [infant]/lim OR [child]/lim OR [preschool]/lim OR [school]/lim OR [adolescent]/lim)

#11 #9 NOT #10

#12 #11 AND [english]/lim AND [2006-2017]/py

#13 (utilit* NEAR/2 (measure* OR outcome* OR state* OR health OR score* OR weight* OR analysis)):ab,ti OR 'health utility index' OR 'hui' OR utilit* NEXT/1 (score* OR value* OR evaluation*) OR health NEXT/2 utilit* OR ('health'/exp OR 'health' AND state NEXT/1 utilit*) OR hui OR (health NEXT/1 state* AND state* NEXT/1 preference*) OR 'quality adjusted life year'/exp OR 'quality adjusted life year' OR 'quality adjusted life' OR 'quality adjusted' NEXT/1 survival* OR qaly* OR qald* OR qale* OR qtime* OR 'disability adjusted life' OR daly* OR hye* OR health*year*equivalent OR health NEAR/2 utility* OR standard NEAR/2 gamble OR disutili* OR time NEAR/2 trade*off OR tto OR 'discrete choice' NEXT/1 experiment* OR 'short form 36'/exp OR 'short form 36' OR 'sf36' OR 'sf-36' OR 'sf 36' OR 'short form 12'/exp OR 'short form 12' OR 'sf12' OR 'sf-12' OR 'sf 12' OR 'short form 6' OR 'sf6' OR 'sf-6' OR 'sf 6' OR 'euroqol' OR euro*qol OR 'eq5d' OR 'eq-5d' OR 'eq 5d' OR rosser OR (visual NEXT/1 analog* AND analog* NEXT/1 scale*)

#14 #1 AND #13

#15 #14 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/lim OR [review]/lim)

#16 #14 AND [animals]/lim

#17 #14 AND ([embryo]/lim OR [fetus]/lim OR [newborn]/lim OR [infant]/lim OR [child]/lim OR [preschool]/lim OR [school]/lim OR [adolescent]/lim)

#18 #15 OR #16 OR #17

#19 #14 NOT #18 AND [2006-2020]/py

1

#20 #12 OR #19

Table S2 Search Strategy for Humanistic Review Conducted for Cochrane

# Search history

#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees

#2 MeSH descriptor: [Bronchitis, Chronic] explode all trees

#3 MeSH descriptor: [Emphysema] explode all trees

#4 (chronic* near/3 bronchiti*):ti,ab,kw

#5 (emphysema* or copd or coad):ti,ab,kw

#6 (obstruct* near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)):ti,ab,kw

#7 #1 or #2 or #3 or #4 or #5 or #6

#8 ((utilit*) near/2 (measure* or outcome* or state* or health or score* or weight* or analysis))

#9 “health utility index” or hui

#10 hrqol or hqol or hrql

#11 MeSH descriptor: [Quality of Life] explode all trees

#12 quality of life or qol

#13 utilit* next/1 (score* or value* or evaluation*)

#14 health next/2 utilit* or ('health' and state next/1 utilit*)

#15 “quality adjusted life year” or “quality adjusted life”

#16 MeSH descriptor: [Quality-Adjusted Life Years] explode all trees

#17 ("quality adjusted" next/1 survival*)

#18 qaly* or qald* or qale* or qtime*

#19 “disability adjusted life” or daly*

#20 “health survey” or hye* or “health year equivalent”

#21 MeSH descriptor: [Health Care Surveys] explode all trees

#22 health near/2 utility*

#23 wellbeing or quality near/2 well*being or qwb

#24 willingness near/2 pay

#25 standard near/2 gamble

#26 disutili*

#27 time near/2 trade*off or tto

#28 "short form 36" or "sf36" or "sf-36" or "sf 36"



#31 euroqol or euro*qol or "eq5d" or "eq-5d" or "eq 5d"

#32 rosser

#33 qlq*

#34 “visual analogue scale” or (visual analog*) or ‘vas’

#35 “st george?s respiratory questionnaire” OR “sgrq”

#36 “treatment satisfaction questionnaire for medication” OR “tsqm”OR ((treat* OR medi*) NEAR/3 satisfact*)

#37 “patient reported outcome*”

#38 “tdi”OR “mrc”OR “medical research council dyspnoea scale”OR “emsci”OR “cat”OR “copd assessment test”OR “ccq”OR “clinical copd questionnaire”OR “chronic respiratory disease questionnaire”OR “crq”

#39 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38

#40 #7 AND #39 AND Publication Year from 2006 to 2020

2

Table S3 Search Strategy for Humanistic Review Conducted for MEDLINE® In-

Process

# Search history

#1 Search “chronic obstructive lung disease”

#2 Search (“chronic bronchitis” OR emphysema)

#3 Search (chronic*) AND bronchiti*

#4 Search (obstruct*[Title/Abstract]) AND (pulmonary OR lung* OR airway* OR airflow* OR bronch* OR respirat*[Title/Abstract])

#5 Search #1 OR #2 OR #3 OR #4

#6 “quality of life” OR “quality of life” OR “quality-of-life” OR “quality-of-life” OR qol

#7 utilit* AND (score* OR value* OR evaluation* OR health)

#8 health AND state AND utilit*

#9 health AND state* AND preference*

#10 hui OR “quality adjusted life year” OR “quality adjusted life year” OR “quality adjusted life” OR (“quality adjusted” AND survival*)

#11 qaly* OR qald* OR qale* OR qtime* OR “disability adjusted life” OR daly* OR”health survey” OR “health survey”� OR hye* OR health*year*equivalent OR (health AND utility*)

#12 wellbeing OR (quality AND well*being) OR qwb

#13 (willingness AND pay) OR (standard AND gamble) OR disutili* OR (time AND trade*off) OR tto OR (“discrete choice” AND experiment*)

#14 “short form 36”OR sf36 OR “sf-36” OR “sf 36” OR “short form 12” OR sf12 OR “sf-12” OR “sf 12” OR “short form 6” OR sf6 OR “sf-6” OR “sf 6” OR euroqol OR euro*qol OR “eq5d” OR “eq-5d” OR “eq 5d” OR rosser

#15 visual AND analog* AND scale*

#16 “st george?s respiratory questionnaire” OR “sgrq”

#17 “treatment satisfaction questionnaire for medication” OR “tsqm”OR ((treat* OR medi*) NEAR/3 satisfact*)

#18 “patient reported outcome*”

#19 “tdi”OR “mrc”OR “medical research council dyspnoea scale”OR “emsci”OR “cat”OR “copd assessment test”OR “ccq”OR “clinical copd questionnaire”OR “chronic respiratory disease questionnaire”OR “crq”

#20 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19

#21 Search #5 AND #20

#22 Search #21 AND (inprocess[sb] OR pubstatusaheadofprint)

3

Table S4 Patient Characteristics of COPD Studies Included in the HRQoL Review

Author Name and Year

n GOLD Severity

Predicted FEV1

(%)Population Analyzed

StudyType

Age (years) Male Non-

smokerCurrent Smoker

Ex-smoker

Smoking Pack-years

Mean (SD) or median (IQR)

Mean (SD) or Median (IQR)

% % % %Mean (SD) or Median

(IQR)

Australia

Kyoong 20061 13 Moderate 55.5 (3.1)GOLD moderate

in COPD-X moderate patients

Cross-sectional 67.5 (4.7) 69 56.9 (24.0)

Kyoong 20061 9 Severe 44.9 (1.5)GOLD severe in

COPD-X moderate patients

Cross-sectional

67.2 (10.7) 22 50.0 (39.1)

Kyoong 20061 11 Severe 36.1 (2.5)GOLD severe in COPD-X severe

patients

Cross-sectional 72.3 (3.2) 64 40.2 (21.3)

Kyoong 20061 6 Very severe 22.0 (4.5)GOLD very severe in COPD-X severe

patients

Cross-sectional 67.7 (9.4) 83 50.0 (10.5)

McGlone 20062 65 Moderate to very severe 46 (16)

Participation in non-walking

activities

Cross-sectional 69.0 (8.0) 42 27 55 (25)

McGlone 20062 59 Moderate to very severe 45 (16)

No participation in non-walking

activities

Cross-sectional 72.0 (8.0) 79 35 59 (34)

Mckellar 20083 24 Severe 38.4 (15.3)

Severe COPD: ≤2 admissions

Cross-sectional 65.0 67 0 17 83

Mckellar 20083 8 Very Severe 29.4 (12.5)

Very severe COPD: ≥3

Cross-sectional

68 63 0 13 87

4


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

admissions

Sloots 20174 82 Severe39

(31–45)Severe COPD Retrospective

study 73.4 (9.9) 46 2.4 8.5 89.0 40

Williams 20175 84 Moderate to very severe

47.9 (16.6)

Moderate to very severe COPD (>80

% of patients)

Cross-sectional 69.7 (8.9) 56

Canada

Chen 20186 91 GOLD II–IV (>80%)

51.1 (21.2)

Moderate to very severe (>80%)

Cross-sectional 70.7 (9.5) 57 41.5 (25.9)

Gupta 20167 716 GOLD I–III+ 82.3 (19.3)

Overall (~45 % of patients with

moderate to very severe COPD)

Prospective 60 27.2 18.3 54.5

Shah 20208 240 GOLD II–IV Moderate to very severe COPD

Cross-sectional

66.7 (10.2) 54

China

Chen 20139 1421 Mild to very severe

GOLD A–D (>80 % of patients with moderate to very

Cross-sectional

5


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

severe COPD)

Chen 201410 154 Severe to very severe 32.7 (9.2) Severe to very

severeCross-

sectional 72.9 (8.1) 99 3.3 12.3 84.4

Gao 201311 218 Mild to very severe

47.3 (14.3)

Overall (>70 % of patients with


Case-control study 66.7 (7.4) 84 8.3 64.7 27.1 35.0 (23.5)

Lou 201212 1100 Mild to very severe

45.2 (10.8)



Cross-sectional +

case-control

63.2 (40–75)

75 55.5 20.5 24.0

Tao 201713 167 Mild to very severe

48.4 (18.8)



Cross-sectional 69.1 (6.9) 64 34.1 18.0 47.9

Wiklund 201014 286 Mild to very severe 52 (22.1)

Overall (>50 % of patients with severe to very severe COPD)


Wu 201515 678 Moderate to very severe 54.5 (23)



Cross-sectional

70.4 (10.1) 73 19.4

Xiang 201516 142 GOLD I–IVModerate to very

severe COPD (>80 % of patients)

Case-control 73.9 (6.2) 83

Yang 202017 210 NR Patients with acute exacerbations

Cross-sectional

71.1 (12.2) 86

6


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Zhang 201518 33 GOLD III–IV 35.4 (6.5) GOLD III–IV

groupCase-control

study68.8

(11.2) 67

Zhou 20186 372 GOLD II–IV 48.6 (18.9)



Cross-sectional 62.2 (8.3) 86 40 (32.2)

France

Beaumont 201819 50 GOLD III–IV 35.7 (8.8) Severe to very

severeProspective

observational 66.7 (7.8)

Le Rouzic 201820 835 GOLD II–IV 47.7 (15.6)

Moderate to very severe COPD

Prospective observational 66.3 (9.6) 80 24.7 75.3 44.4 (19.8)

Germany

Kühl 200821 143 Moderate to very severe

62.9 (9.6) to 26.4 (2.8)


Cross-sectional 67 (9.5) 78 4.9 21.7 73.4

Menn 201022 117 GOLD III–IV

Severe COPD (≤70% of patients)

Prospective observational 67.5 63 16

Mewes 201623 502 Mild to very severe



Cross-sectional 59.7 (8.7) 47 5 16 79

Vaske 201724 444 Mild to very severe




7


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Von Siemens 201925 948 GOLD II 62.6 (8.3) Moderate COPD Prospective 65.7 (8.4) 60 28.6 50.9 (37.5)

Von Siemens 201925 863 GOLD III 40.7 (5.6) Severe COPD Prospective 65 (8.2) 61 21.8 48.4 (34.8)

Von Siemens 201925 241 GOLD IV 24.8 (3.9) Very severe COPD Prospective 62.2 (7.9) 65 14.5 48.5 (33.5)

Von Siemens 201925 567Overall

(GOLD I–IV)

47.6 (16.6) GOLD B Prospective 66.2 (8.1) 62 22.9 53.0 (36.9)

Von Siemens 201925 523Overall

(GOLD I–IV)

42.4 (15.2) GOLD D Prospective 64.6 (8.0) 58 17.8 49.9 (36.8)

Wacker 201626 2291 Mild to very severe

52.5 (18.6)



Cross-sectional 65.1 (8.4) 61 6.6 24.7 68.8

Italy

Bonfitto 201727 35 NR 51.7 (11.8)

Patients with acute exacerbation

Prospective observational

75.3 (6.45) 57

Braido 201528 694 Moderate 64.1 (9.1) Moderate COPD Cross-sectional 70.2 (9.7) 75 9.7 27.8 62.5

Di Marco 200629 202 Mild to very severe

54.0 (1.0) Overall (>85 % of patients with

Case-control study

68.0(1.0)

77

8


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

(>80%) moderate to very severe COPD)

Dignani 201630 102 Mild to severe

59.3 (20.6)

Overall (>85% of patients with


Cross-sectional

73.0 (IQR 10)

75 9.8 13.7 76.5

Ivziku 201931 80 GOLD I–IV

Overall (>55% of patients with severe to very severe COPD)

Cross-sectional

76.4 (7.33) 56

Spain

Almadana 201232 34 NR NR Prospective observational

Balcells 200933 342 Moderate to very severe

47.0 (16.5)

Overall (~95% of patients with


Cross-sectional 67.5 (8.5) 93 0.6 42.4 57.0 65.9 (41.2)

Carrasco-Garrido 200634 10,711

Mild to severe

(SEPAR criteria)

35.9 (10.0) Overall Observationa

l 64.1 (9.7) 76 23.2 19.0 57.8

Esteban 200935 304 Mild GOLD/ATS-ERS; mild COPD

Prospective observational 66.1 (8.9)

Esteban 200935 267 Moderate GOLD/ATS-ERS; moderate COPD


9


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Esteban 200935 40 Severe GOLD/ATS-ERS; severe COPD


Feliz-Rodriguez 201336 45

Mild to severe (≥80%)

51.0 (17.0)



Prospective observational 71 (10.0) 69 2 56 42 51.0 (27.0)

Fernández-García et al 202037 253 Mostly

severe42.1

(14.2)

Patients with severe

exacerbations

Prospective observational 68.9 (9.8) 77 3.6 37.9 58.5 54.2 (29.1)

Izquierdo 200938 3619 GOLD I–IV

Overall (~80 %

of patients

with moderate to very severe COPD)

Overall Cross-sectional

67.0 (10.8) 75 20.5 22.7 56.7

Lopez-Campos 201539 1212 Mild to very

severe61.6

(20.2)Mild to very

severeCross-

sectional 66.4 (9.7) 79 26.2

Martin 200840 9405 Mild to severe

55.1 (14.3)

Overall (66 % of patients with

moderate to severe COPD)

Cross-sectional 67.8 (9.8) 80 16.0 22.6 61.4

Medinas Amoros 200941 64 Moderate to

very severe38.2

(16.6)Moderate to very

severe COPDCross-

sectional 70.1 (9.0)

10


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Merino 201942 386 GOLD I–IV 66.7 (22.3)



Cross-sectional

71.8 (10.3) 76 13.7 16.7 69.6

Miravitlles 2011 (ESFERA Study)43 346 Mild to very

severe46.9

(17.0)



Prospective observational 68.5 (9.5) 91 19.3 50.9 (29.5)

Miravitlles 201544 497 Mild to severe

47.1 (17.5)

Patients with Moderate to severe

exacerbation


Miravitlles 200745 222 GOLD stage II or higher

49.2 (15.4)


Prospective observational 68.2 (9.9) 95 51.4 (28.3)

Miravitlles 200946 827 Mild to very severe

54.6 (17.7)



Cross-sectional

69.0 (10.0) 87 21.6 75.1 47.0 (28.0)

Moro 2009 (MUVICE study)47 1786

Mild to severe

(according to SEPAR criteria)

58.5 (13.9)

Mild to severe COPD

Cross-sectional

66.5 (11.0) 0 57.3 16.1 26.7 33.8 (17.5)

Pinto 201048 75 Mild to very severe

77.5 (26.0)

Overall (31 % of patients with

COPD)

Cross-sectional

60.4 (18.8) 65 14.7 40

Ramon 201749 5969 GOLD A–D 50.7 Overall (>95% of Retrospective 67.5 (9.6) 86 23.4

11


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

(17.2)patients with


Soler-Cataluña 201650 605 Mild to very severe

53.3 (20.7)



Prospective observational 66.9 (8.7) 61 28.9 41 (23.2)

Soler-Cataluña 201650 122 Mild to severe

50.5 (19.4)




Spain, Italy, and Germany

Celli 201751 334 GOLD I–IV



Cross-sectional 58 38.6

UK

Knolle 201152 14 Severe Severe COPD: patients admitted

Prospective observational 74.1

Lawrence 201753 370 GOLD A–D Overall (>89% GOLD B–D)

Prospective observational 70.2 (8.8) 65 30.0 46.0

Lawrence 201753 107 Moderate GOLD B Prospective observational 67 36.5 45.0

Mackay 201254 75 Moderate to very severe

47.9(16.3)

Overall Prospective observational

71.3(8.4)

57 2752.2

(39.9)

12


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Mi 201755 112 GOLD IV Very severe COPD


Parshall 200856 127 Mild to very severe

49.7 (18.6)



Prospective observational 69.4 (8.2) 63

Roberts 201257 18 Moderate to very severe 53.0 Moderate to very

severe COPDProspective

observational 68.0 (8.0) 55 5.5 27.8 66.7

Yeo 200658 27 Mild to severe



Prospective observational 76.0 (4.4) 59

USA

Adams 201259 158 Mild to very severe 41 (16) GOLD A–D Cross-

sectional 66 (9) 78

Coultas 201360 259Moderate to very severe

(>80%)GOLD stage II–IV Cross-

sectional 68.7 (9.5) 51

Dhamane 201661 938 Moderate Moderate COPD Cross-sectional 57.1 (9.7) 53 17.7 43.6 38.7

Dhamane 201661 175 Severe Severe COPD Cross-sectional 58.3 (9.6) 55 14.3 39.4 46.3

Felker 201062 25 Moderate Moderate COPD Cross-sectional

68.0 (10.6)

Felker 201062 38 Severe severe COPD Cross-sectional 66.9 (8.9)

13


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Felker 201062 26 Very severe Very severe COPD

Cross-sectional 67.5 (8.9)

Han 201363 1109 Moderate 68 (13) GOLD B Prospective observational

62(9)

53 55 54 (30)

Han 201363 173 Severe 41 (7) GOLD C1 Prospective observational

66(8)

60 34 50 (24)


65 (8)

32 21 44 (19)


65 (5)

60 10 62 (22)

Han 201363 1182 Very severe 41 (7) GOLD D1 Prospective observational 65 (8) 59 32 57 (29)

Han 201363 252 Very severe 65 (11) GOLD D2 Prospective observational 61 (9) 44 28 51 (27)

14


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Han 201363 403 Very severe32

(10)GOLD D3 Prospective

observational 63 (8) 53 28 55 (27)

Jackson 201464 86 Moderate to very severe

49.0(12.9)

High pain quartile Cross-sectional 64.9 (9.6)

Jackson 201464 75Moderate to very severe

(FEV1 <70%)

41.9 (13.1) Low pain quartile Cross-

sectional 70.1 (8.7)

Jain 201265 41 Moderate to severe

53.6 (15.8)

Moderate to severe COPD

Prospective observational 65.1 (8.8) 61.8 (45.7)

Joo 200866 44 GOLD III–IV

Severe to very severe COPD

Prospective observational 71.5 (7.2) 4.5 18.2 77.3 55.9 (28.5)

Kapella 200667 62 Moderate to severe

46.1 (18.4) Women Cross-

sectional 68.7 (6.7) 0

Kapella 200667 62 Moderate to severe

44.5 (17.9) Men Cross-

sectional 69.5 (5.8) 100

Krishnan 200668 495 Moderate to very severe

66.2 (12.4)

Moderate to severe COPD

Cross-sectional

64.2 (10.0) 55 24.2 27.1 48.7 27.6 (26.5)

Lambert 201769 2383 Moderate to severe 49 (19)

Normal/overweight

patients

Prospective observational 63 (9) 57 43 53 (28)

15


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Lambert 201769 748 Moderate to severe 53 (17) Obesity Class I Prospective

observational 64 (9) 57 37 53 (27)

Lambert 201769 316 Moderate to severe 53 (16) Obesity Class II Prospective

observational 62 (8) 42 34 56 (28)

Lambert 201769 184 Moderate to severe 53 (14) Obesity Class III Prospective

observational 61 (9) 38 40 51 (27)

Leidy 201170 222 Moderate to very severe

50.5 (20.4) Acute group Prospective

observational65.1

(10.5) 47 32

Leidy 201170 188 Moderate to very severe

51.2 (19.6) Stable group Prospective

observational 65.8 (9.7) 48 31

Martinez 201671 1927 Mild to very severe

54.9(22.5)

Older adults Cross-sectional 71.0 (4.0) 57 21.5

57.2(29.9)

Martinez 201671 2170 Mild to very severe

58.2 (22.9)

Middle-aged adults

Cross-sectional 58.3 (4.2) 55 57.3 49.1 (24.5)

Omachi 201372 1202 Moderate to very severe 62 (23) Overall Prospective

observational 58.2 (6.2) 43

Paulin 201273 84 Moderate to severe 55 Moderate to severe

COPDProspective

observational 69 58 56

16


n GOLD Severity

Predicted FEV1


StudyType



Ex-smoker

Smoking Pack-years




(IQR)

Pinto-Plata 201374 31 Moderate to very severe 35 (12) Non-survivor Prospective

observational 67 (10) 68

Pinto-Plata 201374 29 Moderate to very severe 45 (15) Survivor Prospective

observational 68 (7) 59

Solem 201375 190 Severe 48.7 (12.0) Severe COPD

Cross-sectional +

Retrospective chart review

67.4 (9.8) 50 7.9 27.9 64.2

Solem 201375 124 Very severe 40.1 (14.8)

Very severe COPD

Cross-sectional +

Retrospective chart review

68.8 (9.2) 54 2.4 27.4 70.2

Talley 200976 36Moderate to very severe

(FEV1 <80%)


Cross-sectional 59 (12) 47 36.5

(23.25)

Vaz Fragoso 201677 10131 Mild to severe COPD



Prospective observational 59.6 (9.0) 53 52.3 47.7 44.3 (24.9)

Abbreviations: ATS, American Thoracic Society; COPD, chronic obstructive pulmonary disease; COPD-X, Australian and New Zealand

guidelines for the management of chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV1, forced expired

volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRQoL, health-related quality of life; IQR,

interquartile range; NR, not reported; SD, standard deviation; SEPAR, Spanish Society of Pulmonology and Thoracic Surgery.

17

Table S5 Scoring From Critical Appraisal of Individual Studies Included in the HRQoL Review Using Gill and Feinstein Criteria

Criteria Did the investigator give a definition of quality of life?

Did the investigators state the domains they will measure as components of quality of life?

Did the investigators give reasons for choosing the instrument they used?

Did the investigator aggregate results from multiple items, domains or instruments into asingle composite score for quality of life?

Were patients asked to give their own global rating for quality of life?

Was overall quality of life distinguished from health-related quality of life?

Were the patients invited to supplement the items listed in the instruments offered by theinvestigators that they considered relevant for their quality of life?

If so, were these supplemental items incorporated into the final rating?

Were patients allowed to indicate which items were personally important to them?

If so, were the importance ratings incorporated into the final rating?

Summary score

Total criteria complied

Kyoong 20061 0 1 0 1 0 0 0 NA 0 NA 25 2

McGlone 20062 1 1 0 1 0 1 0 NA 0 NA 50 4

Mckellar 20083 0 1 0 1 0 0 0 NA 0 NA 25 2

Sloots 20174 0 1 0 0 NA 0 NA NA NA NA 12.5 1

Williams 20175 0 1 0 1 0 0 0 NA 0 NA 25 2

Chen 201878 0 1 0 1 0 1 0 NA 0 NA 37.5 3

Gupta 20167 0 1 0 1 0 0 0 NA 0 NA 25 2

Shah 20208 0 1 0 1 0 1 NA NA NA NA 37.5 3

Chen 20139 0 0 0 0 0 0 0 NA 0 NA 0 0

Chen 201410 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Gao 201311 0 1 0 0 0 0 0 NA 0 NA 12.5 1

18

Lou 201212 0 1 0 1 0 0 0 NA 0 NA 25 2

Tao 201713 0 1 0 1 0 0 0 NA 0 NA 25 2

Wiklund 201014 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Wu 201515 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Xiang 201516 1 1 0 1 0 0 0 NA 0 NA 37.5 3

Yang 202017 0 1 0 1 0 0 0 NA 0 NA 25 2

Zhang 201518 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Zhou 20186 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Beaumont 201819 0 1 0 1 0 0 0 NA 0 NA 25 2

Le Rouzic 201820 0 1 0 1 0 0 0 NA 0 NA 25 2

Kühl 200821 0 1 0 1 0 1 0 NA 0 NA 37.5 3

Menn 201022 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Mewes 201623 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Vaske 201724 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Von Siemens 201925 0 1 0 1 0 0 0 NA 0 NA 25 2

Wacker 201626 0 1 0 1 0 0 0 NA 0 NA 25 2

Bonfitto 201727 0 1 0 1 0 0 0 NA 0 NA 25 2

Braido 201528 0 1 1 1 1 0 0 NA 0 NA 50 4

Di Marco 200629 0 1 1 1 0 0 0 NA 0 NA 37.5 3

Dignani 201630 1 1 0 1 0 0 0 NA 0 NA 37.5 3

Ivziku 201931 0 1 1 1 1 0 0 NA 0 NA 50 4

Almadana 201232 0 0 0 0 0 0 0 NA 0 NA 0 0

19

Balcells 200933 0 1 0 1 0 0 0 NA 0 NA 25 2

Carrasco-Garrido 200634 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Esteban 200979 0 1 0 1 0 0 0 NA 0 NA 25 2

O’Reilly 200780 0 1 0 1 0 0 0 NA 0 NA 25 2

Feliz-Rodriguez 201336 0 1 0 1 0 0 0 NA 0 NA 25 2

Fernández-García et al 202037 0 0 0 1 0 0 0 NA 0 NA 12.5 1

Izquierdo 200938 0 1 0 1 0 0 0 NA 0 NA 25 2

Lopez-Campos 201539 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Martin 200840 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Medinas Amoros 200941 1 1 0 1 0 0 0 NA 0 NA 37.5 3

Merino 201942 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Miravitlles 2011 (ESFERA Study)43

0 1 0 1 0 0 0 NA 0 NA 25 2

Miravitlles 201544 0 1 0 1 0 0 0 NA 0 NA 25 2



Moro 2009 (MUVICE study)47 0 1 0 1 0 0 0 NA 0 NA 25 2

Pinto 201048 0 1 0 1 0 0 0 NA 0 NA 25 2

Ramon 201749 0 0 0 0 1 0 0 NA 0 NA 12.5 1

Soler-Cataluña 201650 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Celli 201751 0 1 0 0 1 1 0 NA 0 NA 37.5 3

Knolle 201152 0 0 0 0 0 0 0 NA 0 NA 0 0

20

Lawrence 201753 0 1 0 1 0 0 0 NA 0 NA 25 2

Mackay 201254 0 0 0 0 0 0 0 NA 0 NA 0 0

Mi 201755 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Parshall 200856 0 1 1 0 0 0 0 NA 0 NA 25 2

Roberts 201257 0 0 0 0 0 0 0 NA 0 NA 0 0

Yeo 200658 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Adams 201259 0 0 0 0 0 0 NA NA 0 NA 0 0

Coultas 201360 0 0 0 1 0 0 0 NA 0 NA 12.5 1

Dhamane 201661 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Felker 201062 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Vaz Fragoso 201677 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Han 201363 0 1 0 1 0 0 0 NA 0 NA 25 2

Jackson 201464 0 1 0 0 0 0 NA NA 0 NA 12.5 1

Jain 201265 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Joo 200866 0 1 0 1 0 0 0 NA 0 NA 25 2

Kapella 200667 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Krishnan 200668 1 1 0 0 0 0 0 NA 0 NA 25 2

Lambert 201769 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Leidy 201170 0 1 0 1 1 0 0 NA 0 NA 37.5 3

Starkie 201181 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Martinez 201671 0 1 0 1 0 0 0 NA 0 NA 25 2

Omachi 201372 0 1 0 0 0 0 0 NA 0 NA 12.5 1

21

Paulin 201273 0 1 0 0 0 0 0 NA 0 NA 12.5 1

Pinto-Plata 201374 0 0 0 0 0 0 0 NA 0 NA 0 0

Steer 201282 0 1 1 0 0 0 NA NA 0 NA 25 2

Solem 201375 0 1 1 0 0 1 NA NA NA NA 37.5 3

Talley 200976 1 1 0 1 0 1 0 NA 1 NA 62.5 5

Kelly 201183 0 1 1 0 0 0 0 NA 0 NA 25 2

Total number of studies 6 72 13 47 5 7 0 0 1 0

22

References

1. Kyoong A, Mol S, Guy P, et al. Comparison of Australian and international

guidelines for grading severity of chronic obstructive pulmonary disease. Intern

Med J. 2006;36(8):506-512.

2. McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry

and quality-of-life in chronic obstructive pulmonary disease. COPD.

2006;3(2):83-88.

3. McKellar A, Cottrell WN, Whelan A. BODE score is a useful predictor of

hospital admission in rural patients with chronic obstructive pulmonary disease.

Respirology. 2008;13(3):438-443.

4. Sloots JM, Barton CA, Buckman J, et al. The predictive value of an adjusted

COPD assessment test score on the risk of respiratory-related hospitalizations in

severe COPD patients. Chron Respir Dis. 2017;14(1):72-84.

5. Williams MT, John D, Frith P. Comparison of the dyspnoea-12 and

multidimensional dyspnoea profile in people with COPD. The European

respiratory journal. 2017;49(3):1600773.

6. Zhou Z, Zhou A, Zhao Y, Duan J, Chen P. A comparison of the assessment of

health status between CCQ and CAT in a Chinese COPD clinical population: a

cross-sectional analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:1675.

7. Gupta N, Pinto L, Benedetti A, et al. The COPD assessment test: can it

discriminate across COPD subpopulations? Chest. 2016;150(5):1069-1079.

8. Shah A, Ayas N, Tan WC, et al. Sleep quality and nocturnal symptoms in a

community-based COPD cohort. COPD. 2020;17(1):40-48.

23

9. Chen Y, Yao W, Kang J, et al. Distribution and significance of GOLD 2011

disease severity classification in patients with COPD in China: a national cross-

sectional survey. The European respiratory journal. 2013;42:P1870.

10. Chen J, Wong CK, McGhee SM, Pang PK, Yu WC. A comparison between the

EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease

(COPD). PLoS One. 2014;9(11):e112389.

11. Gao Y, Hou Q, Wang H. Assessment of health status in patients with newly

diagnosed chronic obstructive pulmonary disease. PLoS One.

2013;8(12):e82782.

12. Lou P, Zhu Y, Chen P, et al. Prevalence and correlations with depression,

anxiety, and other features in outpatients with chronic obstructive pulmonary

disease in China: a cross-sectional case control study. BMC Pulm Med.

2012;12:53.

13. Tao YX, Wang L, Dong XY, et al. Psychometric properties of the Physical

Activity Scale for the Elderly in Chinese patients with COPD. Int J Chron

Obstruct Pulmon Dis. 2017;12:105-114.

14. Wiklund I, Berry, P, Lu, KX, Fang, J, Fu, C. The Chinese translation of COPD

assessment test™ (CAT) provides a valid and reliable measurement of COPD

health status in Chinese COPD patients. Am J Respir Crit Care Med.

2010;181(1).

15. Wu M, Zhao Q, Chen Y, Fu C, Xu B. Quality of life and its association with

direct medical costs for COPD in urban China. Health Qual Life Outcomes.

2015;13:57.

24

16. Xiang Y, Wong T, Tsoh J, et al. Quality of life in older patients with chronic

obstructive pulmonary disease (COPD) in Hong Kong: a case‐control study.

Perspect Psychiatr Care. 2015;51(2):121-127.

17. Yang Y, Li Q, Mao J, Mao Z. Fatigue and health‐related quality of life among

patients with chronic obstructive pulmonary disease in China. Clin Respir J.

2020;14(2):109-115.

18. Zhang Y, Tu YH, Fei GH. The COPD assessment test correlates well with the

computed tomography measurements in COPD patients in China. Int J Chron


19. Beaumont M, Couturaud F, Jego F, et al. Validation of the French version of the

London Chest Activity of Daily Living scale and the dyspnea-12 questionnaire.

Int J Chron Obstruct Pulmon Dis. 2018;13:1399-1405.

20. Le Rouzic O, Roche N, Cortot A, et al. Defining the “frequent exacerbator”

phenotype in COPD: a hypothesis-free approach. Chest. 2018;153(5):1106-

1115.

21. Kühl K, Schurmann W, Rief W. Mental disorders and quality of life in COPD

patients and their spouses. Int J Chron Obstruct Pulmon Dis. 2008;3(4):727-736.

22. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe

COPD hospitalized for exacerbations – comparing EQ-5D, SF-12 and SGRQ.

Health Qual Life Outcomes. 2010;8:39.

23. Mewes R, Rief W, Kenn K, Ried J, Stenzel N. Psychological predictors for

health-related quality of life and disability in persons with chronic obstructive

pulmonary disease (COPD). Psychol Health. 2016;31(4):470-486.

25

24. Vaske I, Kenn K, Keil DC, Rief W, Stenzel NM. Illness perceptions and coping

with disease in chronic obstructive pulmonary disease: effects on health-related

quality of life. J Health Psychol. 2017;22(12):1570-1581.

25. von Siemens SM, Jorres RA, Behr J, et al. Effect of COPD severity and

comorbidities on the result of the PHQ-9 tool for the diagnosis of depression:

results from the COSYCONET cohort study. Respir Res. 2019;20(1):30.

26. Wacker ME, Jorres RA, Karch A, et al. Assessing health-related quality of life

in COPD: comparing generic and disease-specific instruments with focus on

comorbidities. BMC Pulm Med. 2016;16(1):70.

27. Bonfitto I, Moniello G, Pascucci M, et al. Mood disorders in elderly patients

hospitalized for acute exacerbation of COPD. J Gerontol. 2017;4:13.

28. Braido F, Baiardini I, Scichilone N, et al. Disability in moderate chronic

obstructive pulmonary disease: prevalence, burden and assessment – results

from a real-life study. Respiration. 2015;89(2):100-106.

29. Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in COPD

patients: the roles of gender and disease severity. Respir Med.

2006;100(10):1767-1774.

30. Dignani L, Toccaceli A, Lucertini C, Petrucci C, Lancia L. Sleep and quality of

life in people with COPD: a descriptive-correlational study. Clin Nurs Res.

2016;25(4):432-447.

31. Ivziku D, Clari M, Piredda M, De Marinis MG, Matarese M. Anxiety,

depression and quality of life in chronic obstructive pulmonary disease patients

and caregivers: an actor–partner interdependence model analysis. Qual Life Res.

2019;28(2):461-472.

26

32. Almadana V, Sanchez, J, Gómez-Bastero, A, Valido, A, Pavón, M,

Montemayor, T. COPD assessment test (CAT) in the evaluation of COPD. The

European respiratory journal. 2012;40.

33. Balcells E, Anto JM, Gea J, et al. Characteristics of patients admitted for the first

time for COPD exacerbation. Respir Med. 2009;103(9):1293-1302.

34. Carrasco Garrido P, de Miguel Diez J, Rejas Gutierrez J, et al. Negative impact

of chronic obstructive pulmonary disease on the health-related quality of life of

patients. Results of the EPIDEPOC study. Health Qual Life Outcomes.

2006;4(1):31.

35. Esteban C, Quintana JM, Egurrola M, et al. Classifying the severity of COPD:

are the new severity scales better than the old? Int J Tuberc Lung Dis.

2009;13(6):783-790.

36. Feliz-Rodriguez D, Zudaire, S, Carpio, C, Martínez, E, Gómez-Mendieta, A,

Santiago, A, Alvarez-Sala, R, García-Río, F. Evolution of the COPD

Assessment Test score during chronic obstructive pulmonary disease

exacerbations: determinants and prognostic value. Can Respir J.

2013;20(5):e92-e97.

37. Fernández-García S, Represas-Represas C, Ruano-Raviña A, et al. Social and

clinical predictors associated with prolonged hospital stays for patients with

severe exacerbation of chronic obstructive pulmonary disease. Rev Clin Esp.

2020;220(2):79-85.

38. Izquierdo JL, Barcina C, Jimenez J, Munoz M, Leal M. Study of the burden on

patients with chronic obstructive pulmonary disease. Int J Clin Pract.

2009;63(1):87-97.

27

39. Lopez-Campos JL, Fernandez-Villar A, Calero-Acuna C, et al. Evaluation of the

COPD Assessment Test and GOLD patient types: a cross-sectional analysis. Int

J Chron Obstruct Pulmon Dis. 2015;10:975-984.

40. Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, Gobartt E, de Lucas P.

Health-related quality of life in outpatients with COPD in daily practice: the

VICE Spanish Study. Int J Chron Obstruct Pulmon Dis. 2008;3(4):683-692.

41. Medinas Amoros M, Mas-Tous C, Renom-Sotorra F, Rubi-Ponseti M, Centeno-

Flores MJ, Gorriz-Dolz MT. Health-related quality of life is associated with

COPD severity: a comparison between the GOLD staging and the BODE index.

Chron Respir Dis. 2009;6(2):75-80.

42. Merino M, Villoro R, Hidalgo-Vega Á, Carmona C. Health-related quality of

life of patients diagnosed with COPD in Extremadura, Spain: results from an

observational study. Health Qual Life Outcomes. 2019;17(1):1-10.

43. Miravitlles M, Izquierdo I, Herrejon A, et al. COPD severity score as a predictor

of failure in exacerbations of COPD. The ESFERA study. Respir Med.

2011;105(5):740-747.

44. Miravitlles M, Garcia-Sidro P, Fernandez-Nistal A, et al. The chronic

obstructive pulmonary disease assessment test improves the predictive value of

previous exacerbations for poor outcomes in COPD. Int J Chron Obstruct

Pulmon Dis. 2015;10:2571-2579.

45. Miravitlles M, Molina J, Naberan K, Cots JM, Ros F, Llor C. Factors

determining the quality of life of patients with COPD in primary care. Ther Adv

Respir Dis. 2007;1(2):85-92.

28

46. Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E. Validation

of the COPD severity score for use in primary care: the NEREA study. The

European respiratory journal. 2009;33(3):519-527.

47. Moro JMR-G, Izquierdo JL, Antón E, de Lucas P, Martín A, Group MS. Health-

related quality of life in outpatient women with COPD in daily practice: the

MUVICE Spanish study. Respir Med. 2009;103(9):1303-1312.

48. Pinto JMS, González JR, Arenillas JIC, Nogueras AMM, Gómez FPG. The

health-related quality of life of patients with chronic obstructive pulmonary

disease and asthma evaluated by the SGRQ. Rev Port Pneumol. 2010;16(4):543-

558.

49. Ramon MA, Esquinas C, Barrecheguren M, et al. Self-reported daily walking

time in COPD: relationship with relevant clinical and functional characteristics.

Int J Chron Obstruct Pulmon Dis. 2017;12:1173-1181.

50. Soler-Cataluña JJ, Sauleda J, Valdés L, et al. Prevalence and perception of 24-

hour symptom patterns in patients with stable chronic obstructive pulmonary

disease in Spain. Arch Bronconeumol. 2016;52(6):308-315.

51. Celli B, Blasi F, Gaga M, et al. Perception of symptoms and quality of life–

comparison of patients’ and physicians’ views in the COPD MIRROR study. Int

J Chron Obstruct Pulmon Dis. 2017;12:2189.

52. Knolle M, Challis, B, Pearce, L, Laroche, C, Pulimood, T. Admission avoidance

by hospital at home for exacerbations of COPD by a nurse led team in the east

of England. Am J Respir Crit Care Med. 2011;183(1):1073-1449.

29

53. Lawrence PJ, Kolsum U, Gupta V, et al. Characteristics and longitudinal

progression of chronic obstructive pulmonary disease in GOLD B patients.

BMC Pulm Med. 2017;17(1):42.

54. Mackay A, Donaldson, GC, Patel, AR, Jones, PW, Hurst, JR, Wedzicha, JA.

Usefulness of the chronic obstructive pulmonary disease assessment test to

evaluate severity of COPD exacerbations. Am J Respir Crit Care Med.

2012;185:1218-1224.

55. Mi E, Mi E, Ewing G, et al. Associations between the psychological health of

patients and carers in advanced COPD. Int J Chron Obstruct Pulmon Dis.

2017;12:2813.

56. Parshall MB, Mapel DW, Rice L, Williams A, O'Reilly J. Predictive validity of

short-form health survey [36 items] scales for chronic obstructive pulmonary

disease exacerbation. Heart Lung. 2008;37(5):356-365.

57. Roberts NJ, Patel IS, Kidd L, Lawrence M, Booth J. P32 Does disease severity

affect patient activation scores in COPD? Thorax. 2012;67(Suppl 2):A77.71-

A77.

58. Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD–its

impact on health service utilisation and quality of life, a community study. Age

Ageing. 2006;35(1):33-37.

59. Adams S, Fan V, Nguyen H, et al. Clinical outcomes in chronic obstructive

pulmonary disease are associated with perception of dyspnea more than

exacerbation risk or disease severity measured by lung function. Chest.

2012;142(4):676A.

30

60. Coultas D, Russo, R, Peoples, J, Jackson, BE, Uhm, M, Singh, KP, Ashmore, J,

Bae, S. Self-reported measures of physical activity and health-related outcomes

among patients with COPD. Am J Respir Crit Care Med. 2013;187.

61. Dhamane AD, Witt EA, Su J. Associations between COPD severity and work

productivity, health-related quality of life, and health care resource use: a cross-

sectional analysis of national survey data. J Occup Environ Med.

2016;58(6):e191-197.

62. Felker B, Bush KR, Harel O, Shofer JB, Shores MM, Au DH. Added burden of

mental disorders on health status among patients with chronic obstructive

pulmonary disease. Prim Care Companion J Clin Psychiatry.

2010;12(4):PCC.09m00858.

63. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity

classification in COPDGene: a prospective cohort study. The Lancet Respiratory

medicine. 2013;1(1):43-50.

64. Jackson B, Coultas, DB, Russo, R, Peoples, J, Uhm, M, Singh, KP, Ashmore, J,

Bae, S. Health impact of pain among a representative sample of outpatients with

COPD. Am J Respir Crit Care Med. 2014;189.

65. Jain N, Fulambarker, A, Copur, AS, Nadeem, R, Ghadai, A, Rishi, MA,

Bawaadam, HS, Sethi, A, Quwatli, Z. The effect of hyperinflation measured by

IC/TLC ratio on health status of COPD patients. Am J Respir Crit Care Med.

2012;185:A1516.

66. Joo MJ, Lee TA, Bartle B, van de Graaff WB, Weiss KB. Patterns of healthcare

utilization by COPD severity: a pilot study. Lung. 2008;186(5):307-312.

31

67. Kapella MC, Larson JL, Patel MK, Covey MK, Berry JK. Subjective fatigue,

influencing variables, and consequences in chronic obstructive pulmonary

disease. Nurs Res. 2006;55(1):10-17.

68. Krishnan G, Grant BJ, Muti PC, et al. Association between anemia and quality

of life in a population sample of individuals with chronic obstructive pulmonary

disease. BMC Pulm Med. 2006;6:23.

69. Lambert AA, Putcha N, Drummond MB, et al. Obesity Is associated with

increased morbidity in moderate to severe COPD. Chest. 2017;151(1):68-77.

70. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic

obstructive pulmonary disease exacerbations. Reliability and validity of a

patient-reported diary. Am J Respir Crit Care Med. 2011;183(3):323-329.

71. Martinez CH, Diaz AA, Parulekar AD, et al. Age-related differences in health-

related quality of life in COPD: an analysis of the COPDGene and SPIROMICS

cohorts. Chest. 2016;149(4):927-935.

72. Omachi TA, Gregorich SE, Eisner MD, et al. Risk adjustment for health care

financing in chronic disease: what are we missing by failing to account for

disease severity? Med Care. 2013;51(8):740-747.

73. Paulin L, McCormack, MC, Diette, GB, Belli, AJ, Williams, D, Matsui, EC,

Curtin-Brosnan, J, Aloe, C, Peng, RD, Breysse, P, Hansel, N. Indoor nitrogen

dioxide concentrations are associated with worsening dyspnea in former

smokers with COPD. Am J Respir Crit Care Med. 2012;185:A6633.

74. Pinto-Plata V, Tesfaigzi, Y, Divo, M, Owen, C, Petersen, H, Wang, Y,

Holloway, D, Sanchez, P, Calhoun, V, Martin, S, Celli, BR. Plasma metabolic

32

profile in COPD patients. Association to survival. Am J Respir Crit Care Med.

2013;187:A1519.

75. Solem CT, Sun SX, Sudharshan L, Macahilig C, Katyal M, Gao X.

Exacerbation-related impairment of quality of life and work productivity in

severe and very severe chronic obstructive pulmonary disease. Int J Chron


76. Talley CH, Wicks MN. A pilot study of the self-reported quality of life for

patients with chronic obstructive pulmonary disease. Heart Lung.

2009;38(2):141-150.

77. Vaz Fragoso CA, McAvay G, Van Ness PH, et al. Phenotype of spirometric

impairment in an aging population. Am J Respir Crit Care Med.

2016;193(7):727-735.

78. Chen Y-W, Camp PG, Coxson HO, et al. A comparison of pain, fatigue,

dyspnea and their impact on quality of life in pulmonary rehabilitation

participants with chronic obstructive pulmonary disease. COPD. 2018;15(1):65-

72.

79. Esteban C, Quintana J, Moraza J, et al. Impact of hospitalisations for

exacerbations of COPD on health-related quality of life. Respir Med.

2009;103(8):1201-1208.

80. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated

with COPD exacerbation managed in hospital. Int J Clin Pract.

2007;61(7):1112-1120.

81. Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using

the SGRQ. Value Health. 2011;14(2):354-360.

33

82. Steer J, Gibson GJ, Bourke SC. P83 Relations of Different Quality of Life Tools

to Subsequent Mortality and Readmission of Patients Surviving Hospitalisation

For Acute Exacerbations of COPD: Abstract P83 Table 1. Thorax.

2012;67(Suppl 2):A100.101-A100.

83. Kelly J, Crowley, O, Smith, C, Lim, M, Lord, V, Polkey, MI, Hopkinson, NS.

Determinants of the COPD assessment test (CAT) score in clinical practice. Am

J Respir Crit Care Med. 2011;183(1).

34

Supplementary material Web view40.Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, Gobartt E, de...

Documents

Transcript of Supplementary material Web view40.Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, Gobartt E, de...